Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Class A Common Stock
-
Shares outstanding
-
13.2M
-
Number of holders
-
21
-
Total 13F shares, excl. options
-
771K
-
Shares change
-
+595K
-
Total reported value, excl. options
-
$9.62M
-
Value change
-
+$7.42M
-
Number of buys
-
8
-
Number of sells
-
-1
-
Price
-
$12.47
Significant Holders of Avalo Therapeutics, Inc. - Class A Common Stock (AVTX) as of Q2 2024
21 filings reported holding AVTX - Avalo Therapeutics, Inc. - Class A Common Stock as of Q2 2024.
Avalo Therapeutics, Inc. - Class A Common Stock (AVTX) has 21 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 771K shares
of 13.2M outstanding shares and own 5.86% of the company stock.
Largest 10 shareholders include Logos Global Management LP (539K shares), Sio Capital Management, LLC (71.5K shares), Ikarian Capital, LLC (54.7K shares), Affinity Asset Advisors, LLC (45K shares), COMMODORE CAPITAL LP (40K shares), VANGUARD GROUP INC (10.4K shares), BANK OF AMERICA CORP /DE/ (5.6K shares), UBS Group AG (3.58K shares), Royal Bank of Canada (590 shares), and Banque Cantonale Vaudoise (338 shares).
This table shows the top 21 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.